Moneycontrol
HomeNewsBusinessEconomyMaruti Suzuki Chairman Bhargava: Extension of nationwide lockdown will be a body blow for economy
Trending Topics

Maruti Suzuki Chairman Bhargava: Extension of nationwide lockdown will be a body blow for economy

He said the onus of creating demand in post-COVID 19 era rests on both the government and industry.

April 13, 2020 / 12:42 IST
Story continues below Advertisement

RC Bhargava, Chairman of Maruti Suzuki India, the country's largest passenger carmaker, has strongly recommended resumption of economic activity and voiced his opposition at any further extension of the lockdown period beyond April 14.

In an exhaustive interview with Moneycontrol, he outlined the measures the government should take to recover from this massive setback and said the onus of creating demand in post-COVID 19 era rests on both the government and industry.

Story continues below Advertisement

"Any blanket extension of lockout is not logically required. It was required to identify the hotspots. In 21 days, the hotspots must have already shown up. In rest of the country, start the economic activity but with caution and if there is an inadvertent violation, treat it as a hotspot and cordon it off. But don't shut down economic activity," Bhargava told Moneycontrol.

Asked to detail his plan of action for resumption of economic activity, he said: "I am saying that seal all the hotspots and then open the areas which are free of infection. In those areas, anyone who starts an economic activity should be legally compelled to take certain safeguards related to employees, vendors, transporters and dealers. Point here is that safeguards have to come into play for next few months."

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show